Clostridioides difficile infection (CDI) commonly occurs in people over the age of 65, hospitalized individuals, and individuals with a previous history of CDI and poor immune systems. In addition, CDI can occur following antibiotic treatment due to changes in the balance of the gut microbiome . Reinfection is a common problem in patients who recover from CDI. The USFDA has approved the first fecal microbiota product to prevent the recurrence of CDI in adults.
Fecal microbiota product The fecal microbiota product is manufactured from human stool received from qualified donors . This single-dose biotherapeutic product should be administered rectally. According to the USFDA, the product has been tested for pathogens; however, it may contain food allergens and have a risk of transmitting infectious agents. Nevertheless, the safety and effectiveness of the product were determined in five…
